J Korean Ophthalmol Soc.  2007 Feb;48(2):273-278.

The Effect of Anti-TNF-alpha on Refractory Uveitis

Affiliations
  • 1Department of Ophthalmology, College of Medicine, The Catholic University of Korea, Seoul, Korea. youngjungroh@hanmail.net
  • 2Apgusung St. Mary's Eye Hospital, Seoul, Korea.

Abstract

PURPOSE: To investigate the effects of Anti-TNF-alpha (infliximab, Remicade(R), Shering-Plough) on refractory uveitis.
METHODS
A retrospective observational survey was conducted on 12 eyes of 10 patients with refractory uveitis. These patients had no response to immunosuppresants or systemic steroid therapy and were intolerable due to drug toxicity. After an intravenous injection of Anti-TNF-alpha, best corrected visulal acuity was measured. Improvement in inflammation was then observed at the first, third and last month of follow-up.
RESULTS
Patients were observed for a mean period of 15 months. They received anti-TNF-alpha intravenously, ranging from one to eleven infusions. After infusion with Anti-TNF-alpha, remission of intraocular inflammation was evident in all patients within 9.7 days. Best corrected visual acuity also improved at the first, third, and last month of follow-up. Two patients were infected by tuberculosis and mumps respectively.
CONCLUSIONS
There was an effect on refractory uveitis with anti-TNF-alpha therapy. Many participants may also require further evaluation after treatment.

Keyword

TNF (Tumor necrosis factor); Refractory uveitis

MeSH Terms

Drug-Related Side Effects and Adverse Reactions
Follow-Up Studies
Humans
Inflammation
Injections, Intravenous
Mumps
Retrospective Studies
Tuberculosis
Uveitis*
Visual Acuity
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr